DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA

Abstract

The use of proteasome inhibitors and immunomodulatory drugs in the clinical practice has contributed to the significant improvement in survival for patients with multiple myeloma over the past decades. Alongside this, due to the recurrent course of the disease, there is a need to introduce new classes of drugs to clinical practice. In 2015, the FDA (USA) approved two monoclonal antibodies for use in patients with relapsed multiple myeloma, and immunotherapy has rapidly become indispensable in the management of such patients. The article presents an analysis of the published data regarding the mechanism of action, safety and clinical efficacy of daratumumab, a human monoclonal antibody that targets CD38 tumor protein, for the treatment of patients with multiple myeloma. In Russia, daratumumab is registered (RU LP-004367 of 07.07.2017) and is indicated as monotherapy for patients with relapsed or refractory multiple myeloma, who have received prior therapies, incuding proteasome inhibitors and immunomodulatory drugs. Daratumumab demonstrated an excellent safety profile. In the context of daratumumab therapy, the moderate-grade infusion-related reactions occurring mostly during the first infusion are the main adverse events. Daratumumab-based combination therapies are currently under active evaluation in patients with relapsed and newly diagnosed myeloma.